AMERISAFE Reports Q4 & FY25 Earnings Decline Amid Higher Loss Severity, Boosts Dividend & Repurchases
summarizeSummary
AMERISAFE reported a significant decline in full-year 2025 earnings and an increase in loss severity, but simultaneously raised its quarterly dividend and highlighted substantial share repurchases.
check_boxKey Events
-
Full Year 2025 Earnings Decline
For the full year ended December 31, 2025, net income decreased by 15.0% to $47.1 million, and diluted earnings per share fell by 14.5% to $2.47, compared to the prior year.
-
Increased Loss Severity
The company increased its 2025 accident year loss ratio from 71.0% to 72.0% due to higher-than-anticipated loss severity observed in the fourth quarter.
-
Quarterly Dividend Increase
The Board of Directors increased the regular quarterly cash dividend by 5.1%, from $0.39 to $0.41 per share, payable on March 20, 2026.
-
Significant Share Repurchases
AMERISAFE repurchased 291,289 shares for a total of $12.1 million during 2025, with a remaining share repurchase authorization of $16.9 million as of December 31, 2025.
auto_awesomeAnalysis
AMERISAFE's latest filing presents a mixed financial picture. While the company experienced a notable decline in full-year net income and diluted EPS, coupled with an increase in loss severity for its 2025 accident year, it simultaneously announced a 5.1% increase in its quarterly dividend and detailed significant share repurchases totaling $12.1 million in 2025. The dividend increase and ongoing commitment to share repurchases, especially with the stock trading near its 52-week low, signal management's confidence in the company's long-term value and ability to return capital to shareholders, potentially aiming to offset the negative operational news. Investors will need to weigh the operational challenges, particularly the higher loss severity, against these positive capital allocation decisions.
At the time of this filing, AMSF was trading at $36.89 on NASDAQ in the Finance sector, with a market capitalization of approximately $698.1M. The 52-week trading range was $36.23 to $53.27. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.